Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer (MBC) Clinical Trial

Official title:

A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01495247
• Other study ID #: CBEZ235B2101
• Secondary ID: 2011-002400-32
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: January 30, 2012
• Est. completion date: May 19, 2014

Study information

• Verified date: September 2020
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multi-center, open-label, phase Ib/ II study (two parts) with patients that have locally advanced or metastatic HER2 negative breast cancer. The first part (phase Ib) will investigate the MTD / Recommended Phase 2 Dose (RP2D) of the combination therapy of BEZ235 twice daily (b.i.d.) and weekly paclitaxel using a Bayesian model. When MTD/ RP2D is established the second part (phase II) will start. Phase II will evaluate the efficacy and the safety of weekly paclitaxel alone compared to weekly paclitaxel plus BEZ235 bid.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 18
• Est. completion date: May 19, 2014
• Est. primary completion date: May 19, 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria (phase lb):

• Females with Breast cancer that is histologically or cytologically confirmed, HER2 negative and locally advanced or metastatic as confirmed by radiology

• ECOG performance status 0 and 1

• Adequate bone marrow and organ function

Exclusion Criteria (Phase lb):

• Previous treatment with PI3K and/or mTOR inhibitors

• Symptomatic Central Nervous System (CNS) metastases

• Concurrent malignancy or malignancy in the last 5 years prior to start of study treatment

• Wide field radiotherapy = 28 days or limited field radiation for palliation = 14 days prior to starting study drug

• Active cardiac disease (e.g. LVEF less than institutional lower limit of normal, QTcF > 480 msec, unstable angina pectoris, ventricular, supraventricular or nodal arrhythmias)

• Inadequately controlled hypertension

• Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BEZ235 and/or paclitaxel

• Treatment at start of study treatment with drugs with a known risk to induce Torsades de Pointes, moderate and strong inhibitors or inducers of isoenzyme CYP3A4, warfarin and coumadin analogues, LHRH agonists

• Sensitivity to paclitaxel treatment

• Uncontrolled diabetes mellitus

• Pregnant or nursing (lactating) woman

Other protocol-defined inclusion/exclusion criteria may apply

Related Conditions & MeSH terms

• Breast Neoplasms
• Inoperable Locally Advanced Breast Cancer
• Metastatic Breast Cancer (MBC)

Intervention

Drug:
• BEZ235
Doses of oral BEZ235 (BID), supplied as 50mg, 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.
• Paclitaxel
The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts.

Locations

Country	Name	City	State
France	Novartis Investigative Site	Dijon Cedex
France	Novartis Investigative Site	Saint-Herblain Cédex
Spain	Novartis Investigative Site	Hospitalet de LLobregat	Catalunya

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

France,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase lb: Dose Limiting Toxicities (DLTs) the first cycle of treatment	DLT is defined as treatment-related toxicity (classified according Common Toxicity Criteria for Adverse Events (CTCAE) Version 4) occurring during the first 28 treatment days and meeting specific protocol-predefined criteria.; The information will be integrated in a Bayesian logistic regression model with overdose control to estimate the maximum tolerated dose (MTD).	At first treatment intake (Cycle 1 Day 1 = C1D1), C1D8, C1D15, C1D22 and C2D1 [a cycle = 4 weeks = 28 days]
Secondary	Phase lb: Frequency and severity of adverse events	Incidence of adverse events (based on CTCAE Version 4) summarized by system organ class and/or preferred term, severity and relation to study treatment.	At screening, every week (C1D1, C1D8, C1D15, C1D22, C2D1, C2D8, etc.) until 30-45 days after treatment discontinuation [estimated time frame: 18 months].
Secondary	Phase lb: Progression free survival (PFS)	PFS is defined as the time from start of treatment to objective tumor progression or death from any cause. Radiological assessments will be performed every 8 weeks.	At first treatment intake, every 8 weeks (C3D1, C5D1, C7D1, etc.) until disease progression or death for any cause [estimated time frame: 18 months].
Secondary	Phase lb: Overall Response Rate (ORR)	Proportion of patients with a best overall response of CR or PR according to RECIST 1.1	At first treatment intake, every 8 weeks (C3D1, C5D1, C7D1, etc.) during the study [estimated time frame: 18 months].
Secondary	Phase lb: Clinical Benefit Rate (CBR)	Proportion of patients with a best overall response of CR, PR or SD with a duration of 24 weeks or longer according to RECIST 1.1	At first treatment intake, every 8 weeks (C3D1, C5D1, C7D1, etc.) during the study [estimated time frame: 18 months].

External Links

•   Results for CBEZ235B2101 can be found on the Novartis Clinical Trial Results Website